MSI-H
microsatellite instability-high — A tumor biomarker of defective DNA mismatch repair; MSI-H cancers often respond well to immunotherapy.
If MSI-H is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- Corrigendum to “925MO First-in-human phase I/Ib study of the oral Werner (WRN) helicase inhibitor HRO761 in patients (pts) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors: Interim safety and efficacy analysis from HRO761 single agent dose escalation”: [Annals of Oncology volume 36, supplement 2 (2025) S605-S606] · Annals of Oncology · 2026-08-19
- Cost-effectiveness analysis of Nivolumab plus Ipilimumab versus Nivolumab monotherapy in previously treated metastatic colorectal cancer patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) in China. · Immunotherapy · 2026-08-10
- Neoadjuvant anti-PD-1 monotherapy followed by watch-and-wait strategy in dMMR/MSI-H colorectal cancer: a multicenter real-world study. · Front Immunol · 2026-08-03
- Durable responses to immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients with poor performance status · Clinical Colorectal Cancer · 2026-07-31
- Neoadjuvant PD-1-Based Immunotherapy in Localized dMMR/MSI-H Colorectal Cancer: A Systematic Review and Arm-Based Meta-Analysis. · Cancers (Basel) · 2026-07-29
- Dual CTLA-4/PD-1 Blockade Versus Anti–PD-1 in MSI-H Metastatic Colorectal Cancer: Early Survival Benefit and Exploratory Clinical Predictors · Clinical Colorectal Cancer · 2026-07-25
What the reporting says
It shows up alongside Colorectal Cancer (58), Immunotherapy (45).
Two steps out: AI (through Colorectal Cancer, 58 shared stories on the weaker link); Braf (through Colorectal Cancer, 58 shared stories on the weaker link); ctDNA (through Colorectal Cancer, 58 shared stories on the weaker link); KRAS (through Colorectal Cancer, 58 shared stories on the weaker link).
Tracked since Jan 1, with coverage on 49 separate days — concentrated in Oncology and Pubmed Targeted.